《大行報告》大摩相信藥明康德(02359.HK)股價30日內將升 評級「增持」
摩根士丹利發表技術分析報告,相信藥明康德(02359.HK)股價30日內將升,發生此機會率料70%至80%,予其股份「增持」評級,目標價155元。
該行表示,藥明康德股價於昨日(18日)下跌了8.2%,對比同日恆指為上升0.5%,股價下挫估計或因市場對中國藥品委託開發生產服務(CDMO),及集團與客戶之間在市場授權持有人(MAH)權利方面的關係感到憂慮。此外,市場亦可能憂慮輝瑞(PFE.US)及Moderna(MRNA.US)等藥廠將推出疫苗,或有效控制新型肺炎疫情,令相關治療的外包可能放緩。
不過,大摩認為,藥明康德主要從事小分子研發及生產外包,疫情相關項目並非主要推動力。另外,由於委託生產(CMO)及實驗室服務重啟,集團今年第三季表現遠勝預期,因此該行視是次股價回調為不必要,且為良好的買入機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.